Boothbay Fund Management’s ACELYRIN SLRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-29,828
Closed -$93.7K 1748
2024
Q4
$93.7K Buy
29,828
+10,554
+55% +$51.1K ﹤0.01% 1297
2024
Q3
$95K Sell
19,274
-22,712
-54% -$117K ﹤0.01% 1462
2024
Q2
$185K Sell
41,986
-2,657
-6% -$12.5K ﹤0.01% 1302
2024
Q1
$301K Sell
44,643
-55,703
-56% -$423K 0.01% 1189
2023
Q4
$749K Buy
+100,346
New +$856K 0.02% 822
2023
Q3
Sell
-117,536
Closed -$2.5M 2044
2023
Q2
$2.46M Buy
+117,536
New +$2.4M 0.05% 480

Other funds holding SLRN

Boothbay Fund Management's SLRN Position: Q1 2025 in Review

Boothbay Fund Management sold out of ACELYRIN (SLRN) in Q1 2025, closing a stake of 29,828 shares — an estimated $93.7K sold.

Boothbay Fund Management first reported a position in SLRN in Q2 2023 and held it in 6 quarters. The position peaked at $2.46M in Q2 2023. 105 funds tracked by Wall St. Rank hold SLRN as of Q1 2025.

  • Boothbay Fund Management reported no remaining ACELYRIN position as of Q1 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 29,828 ACELYRIN shares in Q1 2025, an estimated $93.7K.
  • Boothbay Fund Management first reported a position in ACELYRIN in Q2 2023 and held it in 6 quarters.
  • Boothbay Fund Management's ACELYRIN position peaked at $2.46M in Q2 2023.
  • 105 funds tracked by Wall St. Rank held ACELYRIN as of Q1 2025.

Based on Boothbay Fund Management's 13F filing for Q1 2025, filed 15 May 2025.